

1 **Incidence and risk factors associated with acquired syphilis in HIV pre-exposure**
2 **prophylaxis users**

3

4 Nathália Lima Pedrosa^{1*}, Patrícia Matias Pinheiro², Fernando Wagner Brito Hortêncio
5 Filho³, Wildo Navegantes de Araujo^{1,4,5#a}

6

7 ¹ Tropical Medicine Center, University of Brasília, Brasília, Federal District, Brazil

8 ² Walter Cantídio University Hospital, Federal University of Ceará, Fortaleza, Ceará,
9 Brazil

10 ³ Federal Institute of Education, Science, and Technology of Brasília, Brasília, Federal
11 District, Brazil

12 ⁴ UnB Faculty Ceilândia, University of Brasilia, Brasília, Federal District, Brazil

13 ⁵ National Institute for Science and Technology for Health Technology Assessment,
14 Porto Alegre, RS, Brazil

15

16 ^{#a} Current Address: Postgraduate Program in Tropical Medicine, University of Brasilia,
17 Brasília, Federal District, Brazil

18

19 * Corresponding author:

20 E-mail: nati.ufc@gmail.com

21 Phone number: +55 (61) 3107-1678

22 Tropical Medicine Center, University of Brasilia

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23

24 Nathália Lima Pedrosa contributed to the conception, analysis, interpretation of data,
25 and drafting of the work.

26 Patrícia Matias Pinheiro contributed to the conception, analysis, and interpretation of
27 data for the work and reviewing it critically for content.

28 Wildo Navegantes de Araujo contributed to the conception, analysis, and interpretation
29 of data for the work and reviewing it critically for content.

30 Fernando Wagner Brito Hortêncio Filho contributed to analyzing and interpreting data
31 for the work and reviewing it critically for content.

32 All the authors approved the final version of this article, agree to all aspects of this
33 work, and declare that there are no competing interests.

34 **Abstract**

35 **Background:** Acquired syphilis continues to affect millions of people around the
36 world. It is crucial to study it in the context of HIV Pre-Exposure Prophylaxis (PrEP) to
37 achieve the goals set out in the 2030 Agenda since the literature suggests increased risk
38 behaviors for sexually transmitted infections. This study aimed to investigate the
39 incidence and factors associated with acquired syphilis among PrEP users.

40 **Materials and methods:** This retrospective cohort included data on PrEP users from all
41 over Brazil from 2018 to 2020, obtained from the national antiretroviral logistics
42 system. We calculated the proportion of syphilis before PrEP, the incidence during the
43 user's follow-up, reinfections, and their possible associated factors. We conducted
44 descriptive, bivariate, and multivariate analysis, estimating the crude Relative Risk,
45 adjusted Odds Ratio (aOR), and their respective confidence intervals (95%CI).

46 **Results:** Most of the 34,000 individuals who started PrEP were male (89.0%), white
47 (53.7%), self-identified as male (85.2%), homosexual, gay, or lesbian (72.2%), and had
48 12 schooling years or more (67.8%). Of these, 8.3% had syphilis in the six months
49 before starting PrEP, and 4% had it in the first 30 days of using the prophylaxis. In the
50 19,820 individuals effectively monitored, the incidence of acquired syphilis was 19.1
51 cases per 100 person-years, and 1.9% of users had reinfection. The multivariate analysis
52 identified female gender (aOR 0.3; 95%CI 0.2-0.5), being white or Black (aOR 0.9;
53 95%CI 0.7-0.9 and aOR 0.7; 95%CI 0.7-0.99, respectively) as protective factors for
54 syphilis. Being homosexual, gay, lesbian (aOR 2.7; 95%CI 2.0-3.7) or having a history
55 of syphilis in the six months before PrEP (aOR 2.2; 95%CI 1.9-2.5) were risk factors
56 for syphilis during PrEP use. Behaviors related to the risk of syphilis included accepting
57 something in exchange for sex (aOR 1.6; 95%CI 1.3-1.9), irregular condom use (use in

58 less than half of sexual intercourse sessions; aOR 1.7; 95%CI 1.53-2.1) and recreational
59 drug use (poppers; aOR 1.5; 95%CI 1.53-2.1).

60 **Conclusion:** Syphilis in the context of PrEP has high rates and is associated with
61 sociodemographic and behavioral factors. We recommend additional studies targeting
62 prevention in this population to curb these figures.

63 **Keywords:** Syphilis; HIV; PrEP; Cohort; Brazil.

64 INTRODUCTION

65 Acquired syphilis is the most common sexually transmitted infection (STI)
66 worldwide. Although it has been recognized since the 15th century, it continues to
67 represent a contemporary challenge, affecting millions of people, with an annual
68 estimate of 7.1 million (3.8-10.3 million) new infections between 2016 and 2020
69 worldwide [1-3].

70 Syphilis is caused by the spirochete bacterium *Treponema pallidum*. It can
71 result in severe health complications and genital symptoms, including complications
72 during pregnancy, infertility, increased risk of infection by the human
73 immunodeficiency virus (HIV), and psychological impacts if not appropriately treated.
74 The incidence is significantly higher in men who have sex with men (MSM) and in
75 people living with HIV (PLHIV). Appropriate management involves staging the
76 disease, treatment with benzathine penicillin for the individual and their partners,
77 screening in at-risk populations, and notification to health authorities to support control
78 and prevention [2-5].

79 In response to this enduring public health issue, syphilis has been incorporated
80 into the Sustainable Development Goals of Agenda 2030, launched by the United
81 Nations (UN), and the Strategic Guidelines for the Elimination of Sexually Transmitted
82 Infections by the World Health Organization (WHO), which aim to reduce the incidence
83 of *T. pallidum* infections by 90% [1].

84 Besides this setting, Pre-Exposure Prophylaxis (PrEP) has emerged as a crucial
85 strategy in the fight against HIV. Launched in 2012 and widely disseminated globally,
86 the provenly highly effective PrEP involves the use of oral antiretrovirals (ARVs) (in
87 daily doses or on-demand) to reduce the risk of infection by the virus [6]. While PrEP
88 has reduced HIV worldwide, the low use of condoms in individuals using prophylaxis

89 and other “risk compensations” [7] may pose additional challenges in reducing syphilis
90 and achieving the goals set for the 2030 Agenda.

91 Despite the extensive research on PrEP and STIs, there is a dearth of studies
92 analyzing acquired syphilis, its recurrence among PrEP users, and the factors associated
93 with its incidence. These findings could provide critical evidence to strengthen
94 strategies to combat syphilis and help achieve the targets set by the WHO. Therefore,
95 this study aimed to analyze the incidence of acquired syphilis in the population of PrEP
96 users and identify the factors associated with this incidence.

97 **MATERIALS AND METHODS**

98 **Design**

99 This retrospective cohort employed secondary longitudinal data from the
100 Brazilian Ministry of Health’s Medicines Logistics Control System (SICLOM), which
101 is used nationwide to manage the distribution of antiretroviral drugs. This system keeps
102 records of ARV users, both for treatment and prophylaxis, along with clinical and
103 laboratory information on the follow-up of these users [8].

104 The databases extracted from SICLOM, containing information from
105 standardized appointments with PrEP users, were provided by the Ministry of Health
106 after the study was approved by the Ethics Committee of the Faculty of Medicine of the
107 University of Brasília (CAAE: 07448818.0.1001.5558). The data was made available to
108 researchers on March 7, 2021 and were anonymized by removing names, dates of birth,
109 and addresses before being made available to the researchers and replaced by
110 untraceable numerical codes for each study participant in order to guarantee information
111 confidentiality and the protection of PrEP users.

112 During the period in which the database was available (2018-2020) in
113 Brazil, the guidelines standardized care for PrEP users, recommending an initial
114 appointment to collect sociodemographic and behavioral risk data and clinical and
115 laboratory investigation for HIV and other sexually transmitted infections (STIs), using
116 specific forms (Supplement 1). After the first return in 30 days, PrEP users should be
117 followed up every three months for clinical and laboratory follow-up [9]. During the
118 study period, the Unified Health System performed evaluation and follow-up
119 appointments, laboratory tests, and the dispensing of antiretroviral drugs for PrEP at no
120 cost to the user [10].

121 A database was compiled for each form used between 2018 and 2020. The
122 process of qualifying the database of PrEP users is described in Supplement 2. It
123 allowed for following the PrEP user's trajectory from admission to the last available
124 follow-up appointment.

125 **Study population**

126 Considering the target study population as PrEP users, we selected
127 individuals who met the eligibility criteria in the national policy in force at the time [9]
128 for prophylaxis in Brazil, seen between January 2018 and December 2020 and who had
129 at least one follow-up visit. Afterward, users for whom it was impossible to obtain
130 information from any subsequent forms were excluded through a deterministic
131 relationship between the different databases created from the records derived from the
132 completed forms (Supplement 2).

133 In Brazil, the PrEP eligibility criteria include sexually active people with
134 increased risk for HIV, such as sexual practices with penetration without the use of
135 condoms, multiple casual sexual partners, diversity and frequency of sexual

136 partnerships, history of STIs, repeated search for HIV Post-Exposure Prophylaxis
137 (PEP), sexual relationships in exchange for money or material goods, and Chemsex
138 (sexual practice under the influence of psychoactive drugs).

139 While not exclusive, serodiscordant couples and primary populations (gay
140 men, men who have sex with men (MSM), transgender people, and sex workers) should
141 be given preference in the provision of PrEP by the Unified Health System (SUS) [9].

142 **Measures**

143 Data collected consisted of sociodemographic characteristics (genitalia at
144 birth, self-reported ethnicity/skin color, gender identity, sexual orientation, age, and
145 schooling years), behavioral characteristics in the last three months (sex in exchange for
146 money/goods, condom use frequency, alcohol consumption, use of injectable drugs and
147 other psychoactive drugs, number and type of sexual partnerships), and health
148 characteristics (history of STIs in the last six months and presence of active syphilis
149 during follow-up). Self-reported ethnicity/skin color is used per the Brazilian Institute
150 of Geography and Statistics (IBGE). We arbitrated the information referring to the last
151 appointment for follow-up behavioral data.

152 In Brazil, the diagnosis of syphilis is guided by clinical evaluation and direct
153 (when with symptoms) or immunological (regardless of symptoms) tests. Concerning
154 the latter, which are more common in routine services, guidelines recommend starting
155 the investigation with a treponemal test (preferably a rapid test) followed by a non-
156 treponemal test (VDRL or RPR) when the first test is positive [11]. The history of
157 acquired syphilis was assessed in the six months before the first appointment through
158 the report of diagnosis or the syphilis serological screening on admission.

159 In this cohort, the duration of follow-up for PrEP users was calculated as the
160 time elapsed between the date of the first visit and the date of the last follow-up visit,
161 regardless of adherence. Moreover, users who did not attend at least one follow-up
162 appointment were considered losses in the cohort and compared with those who did
163 follow up regarding schooling, ethnicity/skin color, and sexual orientation to check for
164 differences between the groups.

165 The incidence of acquired syphilis during PrEP use was measured by the
166 number of “active syphilis” events identified by health professionals after three months
167 of prophylaxis use, obtained from the data on the Monitoring Form, following the
168 method described by Ong [12]. The outcome could also be observed on more than one
169 occasion during the user’s follow-up, and this event was defined as a syphilis
170 reinfection outcome during PrEP follow-up and calculated as another incident event.
171 We could, thus, measure the proportion of users who acquired syphilis at least twice or
172 more during PrEP.

173 **Statistics**

174 We presented the continuous variables (age and number of sexual partners)
175 using measures of central tendency (mean and median) and dispersion (standard
176 deviation and interquartile range), and the categorical variables were described using
177 measures of absolute and relative frequency in each category. The individual’s time in
178 the cohort was calculated as the difference between the date of registration in the system
179 (when PrEP started) and the date of the last appointment recorded in the system. The
180 user follow-up period and syphilis incidence were calculated per 100 person-years.

181 Sociodemographic and behavioral variables were compared between
182 individuals diagnosed with syphilis and those who were not diagnosed during follow-

183 up. Subsequently, the bivariate association between the outcome and the covariates was
184 verified using the chi-square or Fisher's exact test for categorical variables and the
185 Wilcoxon test for numerical variables, considering the difference statistically significant
186 if $p < 0.05$. Furthermore, we calculated the Relative Risk (RR) and the 95% Confidence
187 Interval (95% CI) to evaluate the possible factors associated with syphilis infection
188 during PrEP use.

189 We then carried out a logistic regression analysis using the backward-stepwise
190 method to control for confounders. In this regression, we considered active syphilis
191 during PrEP (yes or no) as the dependent variable and the sociodemographic,
192 behavioral, and sexual health variables whose bivariate analysis showed a p-value < 0.2
193 as independent variables. We assessed multicollinearity using Variance Inflation Factors
194 (VIF) and identified the best model using the Akaike Information Criterion (AIC) and
195 pseudo R^2 . Considering the low risk of the outcome in this study, we estimated the
196 Relative Risk adjusted by the adjusted odds ratio (aOR) and its Confidence Intervals
197 (95% CI) to assess the effect of the adjusted covariates on the outcome.

198 The above analyses were performed using the R® 4.3.3 software using the
199 libraries tidyverse, janitor, stringr, rio, here, purrr, gtsummary, broom, lmtest,
200 parameters, see, readxl, plyr, with code provided as supplementary material
201 (Supplement 2).

202 **RESULTS**

203 After linking the databases of PrEP consultation forms, we obtained 34,000
204 records of people who started using PrEP and 19,820 users who followed up and were
205 part of the cohort. The base population of this cohort reflects PrEP users in Brazil
206 between 2018 and 2020, as shown in Table 1. Most PrEP users were male (89.0%),

207 white (53.7%), self-identified as male (85.2%), were homosexuals, gays, or lesbians
208 (72.2%), and had 12 years or more of schooling (67.8%) (Table 1).

209 **Table 1**

210 In total, 19,820 people were effectively followed up, with a median follow-
211 up of seven months (IQR=7-20 months). We observed a loss-to-follow-up rate of 41.7%
212 among those who started PrEP. Similar to the initial cohort, most were men (86%),
213 homosexuals, gays, or lesbians (67%), white (51%), and had 12 years or more of
214 schooling (61%), with $p < 0.001$.

215 Table 2 shows an overview of acquired syphilis among PrEP users. During
216 the initial appointment, 8.3% of individuals reported a history of acquired syphilis, and
217 4.0% of those who returned for follow-up after 30 days were diagnosed with active
218 syphilis.

219 **Table 2**

220 In this cohort, 1,962 individuals (9.8%) received at least one diagnosis of
221 active syphilis during follow-up, and 2% of users had a recurring infection, i.e., more
222 than one episode of syphilis during follow-up. In total, 2,525 diagnoses of active
223 syphilis were recorded, resulting in an incidence of 19.1 cases of acquired syphilis per
224 100 person-years (95% CI 18.4-19.9). There was a high proportion of missed syphilis
225 tests in the 30-day return period (33.4%) and the total number of follow-up
226 appointments (38.8%).

227 To analyze the risk factors associated with acquired syphilis, we compared
228 individual and behavioral characteristics between people with at least one diagnosis of
229 acquired syphilis during follow-up and PrEP users who did not receive such a diagnosis
230 during the period (see Table 3).

231 **Table 3**

232 In the bivariate analysis, statistically significant differences were observed in
233 the following variables: sex at birth, sexual orientation, gender identity (transgender),
234 ethnicity/skin color, schooling years (4-7 years and 12 years or more), having accepted
235 something in exchange for sex, history of previous syphilis in the last six months,
236 frequency of condom use in the last three months, number of sexual partners in the last
237 three months, and alcohol and other psychoactive drugs abuse in the last three months.

238 The multivariate analysis (see Table 3) identified no multicollinearity based on
239 VIF (see Supplement 2). After we identified the most parsimonious model, the variables
240 independently associated with the incidence of syphilis in the cohort were age, sex at
241 birth, self-reported ethnicity/skin color, having accepted something in exchange for sex,
242 history of previous syphilis in the last six months, frequency of condom use in the last
243 three months, number of sexual partners in the last three months (men, women, and
244 transsexuals) and use of poppers, cocaine, marijuana, and erection stimulants.

245 Regarding the risk of acquired syphilis during PrEP use, being a woman was a
246 protective factor (aOR 0.3; 95% CI 0.2-0.5). White and Black people had an 80% lower
247 risk of having syphilis than brown people (95% CI 0.7-0.9 and 0.7-0.99, respectively).
248 Homosexuals, gays, and lesbians were 2.7 times (95% CI 2.0-3.7) more likely to be at
249 risk of having syphilis than heterosexuals. Moreover, individuals with a history of
250 syphilis in the six months before PrEP were 2.2 times (95% CI 1.9-2.5) more likely to
251 be at risk of acquiring syphilis during follow-up.

252 Regarding behaviors reported at the last follow-up visit, people who accepted
253 something in exchange for sex were 1.6 times (95% CI 1.3-1.9) more likely to be at risk
254 of having syphilis than individuals who did not engage in this practice. Irregular
255 condom use increased by at least 1.2 times the risk compared to those who use condoms

256 in all relationships. The use of recreational drugs such as poppers (aOR 1.5; 95% CI
257 1.2-1.9), cocaine (aOR 1.5; 95% CI 1.2-1.7), and marijuana (aOR 1.2; 95% CI 1.01-1.3)
258 is also associated with an increased risk of syphilis during PrEP use. There was also a
259 difference between the groups regarding age and the number of male sexual partners.

260 **DISCUSSION**

261 This research analyzed a cohort using digital records from different stages
262 among PrEP users nationwide to understand the incidence of syphilis in the context of
263 PrEP and its associated factors. Most PrEP users were male, white, self-identified as
264 male, homosexual, gay or lesbian, and had 12 or more schooling years. Our findings
265 revealed a prevalence of 8.3% of syphilis in the six months before starting PrEP, 4% in
266 the first 30 days of prophylaxis use, and 9.8% of all those followed up in this cohort had
267 syphilis during follow-up (with an incidence of 19.1 cases of acquired syphilis per 100
268 people), with 1.9% reinfected users.

269 The multivariate analysis identified female gender as a protective factor
270 against syphilis during PrEP, as with being white or Black. On the other hand, the main
271 risk factors for syphilis during PrEP were identified as being homosexual, gay, or
272 lesbian and having a history of syphilis in the six months before starting PrEP. Risk
273 behaviors associated with syphilis included accepting something in exchange for sex,
274 irregular condom use, and recreational drug use. We also observed significant
275 differences between the groups regarding age and the number of male sexual partners.
276 Moreover, we noted a significant proportion of follow-up appointments without testing
277 or with unavailable tests.

278 Our findings estimated an 8.3% prevalence of syphilis in the six months before
279 starting PrEP. Recent studies of PrEP users in other countries have revealed rates of
280 10.1% (95% CI 7.6-13.1%) in Canada [13], 3.63% (95% CI 2.93-4.44%) in Germany

281 [14] and 25.8% in France [15]. However, it is essential to exercise caution when
282 comparing these studies since the approach to analyzing the history of syphilis before
283 PrEP can vary (interview, history of laboratory tests, and medical records), which can
284 directly influence the prevalence estimates found.

285 The follow-up of PrEP users in Brazil revealed an incidence of 19.1 cases of
286 acquired syphilis per 100 person-years (95% CI 18.4-19.9). This incidence can be
287 considered relatively high against results from other cohorts of PrEP users in Australia
288 (9.4 (9.0-9.8) /100 PA) [16], Canada (1.94 (0.73-5.12) /100 BP) [13], and the United
289 States (7.8 (7.1-8.4) /100 BP) [17], but similar to findings in Denmark (21.7 /100 BP)
290 [18] and Spain (15.99 (11.94-21.41) /100PA) [19]. These regional disparities need to be
291 better investigated. They may reflect vulnerabilities arising from the response of the
292 countries' public policies in the fight against syphilis and the profile of PrEP users in
293 each country.

294 While our findings found 1.9% reinfection, Lemmet et al [15] showed 17.1%
295 of PrEP users followed up in France with reinfection, mainly in older people (aOR 1.31;
296 95% CI 1.04-1.67) and MSM (aOR 2.71; 95% CI 1.89-3.96). However, syphilis
297 reinfection in the context of PrEP is little explored in the studies. It is, therefore,
298 recommended to explore the factors associated with syphilis reinfection in further
299 studies. Our low rate can be explained by the low testing level detected during follow-
300 up appointments, perhaps due to fewer referrals to primary care.

301 Regarding the factors associated with syphilis in the PrEP, the study by
302 Lemmet et al [15] corroborates our findings, as it shows that female gender can be a
303 protective factor, while people with syphilis in PrEP may be 6.6 more likely (CI 95%
304 5.10-8.66) to be men who have sex with men. Our findings also showed female gender
305 as a protective factor, being homosexual, gay, or lesbian, and age as a risk factor. A

306 study conducted by Peel et al [20] in Australia showed that PrEP users diagnosed with
307 syphilis had a mean of 33 years and that, as in our findings, there is evidence that a
308 syphilis history is a relevant risk factor [14, 15].

309 Regarding behaviors associated with syphilis infection during PrEP, our study
310 found a significant association between recreational drug use and syphilis acquired
311 during PrEP, particularly for poppers, marijuana, cocaine, and erection stimulants. One
312 study identified that sexual drugs and chemsex have a significant association with the
313 number of partners, search for partners on the internet, and low condom use with casual
314 partners [21]. These findings may corroborate an increased vulnerability with the use of
315 these substances. Hetcher et al [17] emphasizes that the relationship between the use of
316 these substances and STIs needs to be examined more directly in order to understand
317 the mechanisms that promote the vulnerability of individuals when they are using these
318 substances. Indeed, understanding how these fragilities operate in the health-disease
319 process for syphilis can facilitate management during PrEP to prevent this infection and
320 other STIs.

321 Although the highest proportion of PrEP users are white (53.7%), this category
322 of the ethnicity/skin color variable has an 80% lower risk of syphilis infection than
323 brown people. In the Brazilian population, most people self-declare brown (45.3%) or
324 white (43.5%) [22], and this can be investigated in future studies in light of the unequal
325 access to PrEP in Brazil. In Brazil, equitable access by law to health resources through
326 the health decentralization policy of the Unified Health System has significant
327 challenges, considering that it offers a universal system to more than 180 million
328 inhabitants. The unequal distribution of health resources is a persistent reality in several
329 contexts and is a complex issue [23]. However, the possible unequal distribution of
330 PrEP would occur not only in Brazil but also among Americans [24].

331 Furthermore, we observed significant follow-up appointments without testing
332 or unavailable tests. The COVID-19 pandemic may have impacted the quality of care
333 involving serological testing [25], which started in 2020 since the provision of services
334 during this period was adversely affected, with outpatient sexual and reproductive
335 health services adopting models of care that avoided face-to-face appointments and
336 hospitals with shortened appointments in order to reduce the number of people in
337 hospital environments. Moreover, people from the lesbian, gay, bisexual, transgender,
338 queer, intersex, and agender (LGBTQIA+) community, a primary population for PrEP,
339 can face barriers in health services due to misgendering, stigma, and attitudes that can
340 generate bad experiences for them, interfering with their healthcare [26]. Individual
341 service and social issues, such as improving the convenience of testing through self-
342 testing and offering a service that men feel comfortable and safe accessing, should be
343 considered by health services to make STI testing more accessible to MSM [27].
344 Serological testing for both syphilis and other STIs is a relatively simple and low-cost
345 technology in the care of PrEP users. It should be prioritized in the context of inputs for
346 primary health services.

347 Differentiated approaches to syphilis should be considered for this specific
348 subgroup of PrEP users. Initially, we could not observe in this Brazilian research an
349 approach to communication with sexual partners for testing and treatment in order to
350 interrupt the chain of transmission of syphilis, although recommendations are in place in
351 this country and elsewhere in the world [9, 28]. Also, the use of social media apps for
352 sexual encounters can favor anonymity and an increase in the number of partners [29].
353 However, this variable may not be addressed during follow-up appointments as it is not
354 included in the guide form for monitoring appointments. It is, therefore, recommended
355 to explore new approaches within PrEP to reduce STIs.

356 Our study has some limitations. Firstly, the proportion of losses in the cohort
357 was high (41%). However, the individual characteristics of those lost to follow-up were
358 similar, proportionally, to those who continued (homosexuals, whites, and with a high
359 schooling level). Secondly, the behavioral variables during follow-up were extracted
360 only from the last visit, which may not have captured changes during PrEP use and the
361 possible influence of these changes on *Treponema pallidum* infection. We recommend
362 studies that analyze the behavior of PrEP users over time. Thirdly, some data were not
363 recorded at the last visit, which can introduce information bias, and a significant
364 proportion of tests was not run on appointments, which can underestimate the actual
365 incidence density of acquired syphilis. Finally, as the data were obtained through
366 interviews conducted by health professionals, there may have been inhibition in
367 responses and underestimation of behaviors due to social desirability. Given the users'
368 schooling level, we should consider using self-administered questionnaires to reduce
369 this bias.

370 These limitations underscore the need for caution in interpreting the results and
371 highlight areas for future research aimed at improving understanding of the factors
372 associated with syphilis in PrEP users and improving the quality of the data collected
373 during follow-up of these individuals. Despite the limitations, our study provides
374 substantial evidence for understanding syphilis during HIV prophylaxis. Besides the
375 high rates of acquired syphilis, the findings related to associated factors can contribute
376 to developing specific public policies geared to the health of homosexual men, those
377 with a history of syphilis, a high number of sexual partnerships, and recreational drug
378 users, curbing syphilis transmission rates and achieving the 2030 Agenda global goals.

379 We should underscore that the high incidence of syphilis among PrEP users
380 should not be seen as a disadvantage of this form of prophylaxis, which could lead to

381 compensatory risk behaviors. This situation requires additional studies beyond
382 secondary data to explore other associated factors. Thus, the detection of syphilis and
383 other STIs should be an integral part of managing these users during follow-up, and
384 PrEP is an essential policy for reducing STI rates.

385 **References**

- 386 1. Almeida MCD, Cordeiro AMR, Cunha-Oliveira A, Barros DMS, Santos DGSM,
387 Lima TS, et al. Syphilis response policies and their assessments: A scoping review.
388 Front Public Health. 2022; 16(10):1002245. doi: 10.3389/fpubh.2022.1002245.
- 389 2. Forrestel AK, Kovarik CL, Katz KA. Sexually acquired syphilis: Historical aspects,
390 microbiology, epidemiology, and clinical manifestations. J Am Acad Dermatol. 2020;
391 82(1):1-14. doi: 10.1016/j.jaad.2019.02.073. Epub 2019 Apr 12. PMID: 30986477.
- 392 3. Tudor ME, Al Aboud AM, Leslie SW, Gossman W. Syphilis [Updated 2023 May
393 30]. Treasure Island (FL): StatPearls Publishing; [Cited 2024 March 29]. Available
394 from: Available from: <https://www.ncbi.nlm.nih.gov/books/NBK534780/>
- 395 4. Forrestel AK, Kovarik CL, Katz KA. Sexually acquired syphilis: Laboratory
396 diagnosis, management, and prevention. J Am Acad Dermatol. 2020; 82(1):17-28. doi:
397 10.1016/j.jaad.2019.02.074. PMID: 30986474.
- 398 5. Pan American Health Organization. Sexually Transmitted Infections 2024 [Cited
399 2024 March 29]. Available from: [https://www.paho.org/en/topics/sexually-transmitted-](https://www.paho.org/en/topics/sexually-transmitted-infections)
400 [infections](https://www.paho.org/en/topics/sexually-transmitted-infections)
- 401 6. Lazarus G, Wangsaputra VK, Christianto, Louisa M, Soetikno V, Hamers RL. Safety
402 and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1
403 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized
404 Trials. Front Pharmacol. 2021;12:664875. doi: 10.3389/fphar.2021.664875. PMID:
405 34305587; PMCID: PMC8299834.

- 406 7. Cannon C, Celum C. Sexually transmissible infection incidence in men who have sex
407 with men using HIV pre-exposure prophylaxis in Australia. *Lancet Infect Dis*. 2022
408 ;22(8):1103-1105. doi: 10.1016/S1473-3099(22)00284-5. Epub 2022 May 25. PMID:
409 35643091.
- 410 8. Ministry of Health of Brazil. Sistema de Controle Logístico de Medicamentos
411 (Siclom) [Updated 2023 July 23]. Brasília: Ministério da Saúde. [Cited 2024 March 25].
412 Available from: <https://www.gov.br/aids/pt-br/sistemas-de-informacao/siclom>
- 413 9. Ministério da Saúde. Protocolo Clínico de Diretrizes Terapêuticas para Profilaxia
414 Pré-exposição para HIV. 2018 [Cited 2024 March 20]. Available from:
415 [http://www.aids.gov.br/publicacao/2017/protocolo-clinico-e-diretrizes-terapeuticas-](http://www.aids.gov.br/publicacao/2017/protocolo-clinico-e-diretrizes-terapeuticas-para-profilaxia-pre-exposicao-prep-de-ri)
416 [para-profilaxia-pre-exposicao-prep-de-ri](http://www.aids.gov.br/publicacao/2017/protocolo-clinico-e-diretrizes-terapeuticas-para-profilaxia-pre-exposicao-prep-de-ri)
- 417 10. Paim J, Travassos C, Almeida C, Bahia L, Macinko J. The Brazilian health system:
418 history, advances, and challenges. *Lancet*. 2011;377(9779):1778-1797.
419 doi:10.1016/S0140-6736(11)60054-8
- 420 11. Ministry of Health of Brazil. Protocolo Clínico de Diretrizes Terapêuticas para
421 Profilaxia Pré-exposição para HIV. 2022 [Cited 2024 March 20]. Available from:
422 [https://www.gov.br/aids/pt-br/central-de-conteudo/pcdts/2017/hiv-aids/pcdt-prep-](https://www.gov.br/aids/pt-br/central-de-conteudo/pcdts/2017/hiv-aids/pcdt-prep-versao-eletronica-22_09_2022.pdf/view)
423 [versao-eletronica-22_09_2022.pdf/view](https://www.gov.br/aids/pt-br/central-de-conteudo/pcdts/2017/hiv-aids/pcdt-prep-versao-eletronica-22_09_2022.pdf/view)
- 424 12. Ong JJ, Baggaley RC, Wi TE, Tucker JD, Fu H, Smith MK, Rafael S, et al. Global
425 Epidemiologic Characteristics of Sexually Transmitted Infections Among Individuals
426 Using Preexposure Prophylaxis for the Prevention of HIV Infection: A Systematic
427 Review and Meta-analysis. *JAMA Netw Open*. 2019; 2(12):e1917134. doi:
428 10.1001/jamanetworkopen.2019.17134. PMID: 31825501; PMCID: PMC6991203.
- 429 13. Candler E, Naeem Khan M, Gratrix J, Plitt S, Stadnyk M, Smyczek P, et al.
430 Retrospective audit of a convenience cohort of individuals on HIV pre-exposure

- 431 prophylaxis in Alberta, Canada. *J Assoc Med Microbiol Infect Dis Can.* 2022; 7(4):350-
432 363. doi: 10.3138/jammi-2022-0016. PMID: 37397818; PMCID: PMC10312220.
- 433 14. Schmidt D, Kollan C, Bartmeyer B, et al. Low incidence of HIV infection and
434 decreasing incidence of sexually transmitted infections among PrEP users in 2020 in
435 Germany. *Infection.* 2023; 51(3):665-678. doi:10.1007/s15010-022-01919-3
- 436 15. Lemmet T, Cotte L, Allavena C, et al. High syphilis prevalence and incidence in
437 people living with HIV and Preexposure Prophylaxis users: A retrospective review in
438 the French Dat'AIDS cohort. *PLoS One.* 2022; 17(5):e0268670.
439 doi:10.1371/journal.pone.0268670
- 440 16. Traeger MW, Murphy D, Ryan KE, et al. Latent Class Analysis of Sexual
441 Behaviours and Attitudes to Sexually Transmitted Infections Among Gay and Bisexual
442 Men Using PrEP. *AIDS Behav.* 2022; 26(6):1808-1820. doi:10.1007/s10461-021-
443 03529-w
- 444 17. Hechter RC, Bruxvoort KJ, Zhou H, et al. Sexually transmitted Infections Among
445 Men and Transgender Women Using HIV Pre-exposure Prophylaxis in a Large
446 Integrated Health System-A Cohort Study. *J Acquir Immune Defic Syndr.* 2022;
447 91(1):1-8. doi:10.1097/QAI.0000000000003015
- 448 18. Azarnoosh M, Johansen IS, Martin-Iguacel R. Incidence of Sexually Transmitted
449 Infections After Initiating HIV Pre-Exposure Prophylaxis Among MSM in Southern
450 Denmark. *Am J Mens Health.* 2021; 15(3):15579883211018917.
451 doi:10.1177/15579883211018917
- 452 19. Iniesta C, Coll P, Barberá MJ, et al. Implementation of pre-exposure prophylaxis
453 programme in Spain. Feasibility of four different delivery models. *PLoS One.*
454 2021;16(2):e0246129. doi:10.1371/journal.pone.0246129

- 455 20. Peel J, Chow EPF, Denham I, et al. Clinical Presentation of Incident Syphilis
456 Among Men Who Have Sex with Men Taking HIV Pre-Exposure Prophylaxis in
457 Melbourne, Australia. *Clin Infect Dis*. 2021; 73(4):e934-e937. doi:10.1093/cid/ciab052
- 458 21. Giacalone S, Barberi F, Ramoni S, Casazza G, Cusini M, Marzano AV. Sexualised
459 drug use and chemsex in Italy: A questionnaire study based on a cohort of clients
460 attending a STI outpatient service in Milan. *Int J STD AIDS*. 2023; 34(14):1034-1041.
461 doi: 10.1177/09564624231193055. PMID: 37608639.
- 462 22. Brazilian Institute of Geography and Statistics. Censo 2022. [Cited 2024 April 04].
463 Available from: <https://censo2022.ibge.gov.br/panorama/>
- 464 23. Mello GA, Pereira APCM, Uchimura LYT, Iozzi FL, Demarzo MMP, Viana ALD.
465 A systematic review of the process of regionalization of Brazil's Unified Health System,
466 SUS. *Cien Saude Colet*. 2017; 22(4):1291-1310. doi: 10.1590/1413-
467 81232017224.26522016. PMID: 28444053.
- 468 24. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. HIV
469 prevention pill not reaching most Americans who could benefit – especially people of
470 color. 2018. [Cited 2024 April 04]. Available from:
471 <https://www.cdc.gov/nchhstp/newsroom/2018/croi-2018-PrEP-press-release.html>
- 472 25. Tam MW, Davis VH, Ahluwalia M, Lee RS, Ross LE. Impact of COVID-19 on
473 access to and delivery of sexual and reproductive healthcare services in countries with
474 universal healthcare systems: A systematic review. *PLoS ONE*. 2024; 19(2): e0294744.
475 <https://doi.org/10.1371/journal.pone.0294744>
- 476 26. Ford, L. G., Lewis, C., & Volberding, J. L. The Perceptions and Experiences
477 Among Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, and Agender Patients of
478 Quality of Care With Health Care Services. *International Journal of Athletic Therapy*
479 *and Training*. 2024. doi:10.1123/ijatt.2022-0140

- 480 27. Kularadhan V, Gan J, Chow EPF, Fairley CK, Ong JJ. HIV and STI Testing
481 Preferences for Men Who Have Sex with Men in High-Income Countries: A Scoping
482 Review. *Int J Environ Res Public Health*. 2022; 19(5):3002. doi:
483 10.3390/ijerph19053002. PMID: 35270694; PMCID: PMC8910668.
- 484 28. Republic of Uganda Ministry of Health. Assisted Partner Notification Training for
485 Providers in Clinical Settings. Uganda, Kampala: 2018. [Cited 2024 April 02]
486 Available from: [https://nastad.org/sites/default/files/2021-12/PDF-Assisted-Partner-](https://nastad.org/sites/default/files/2021-12/PDF-Assisted-Partner-Notification-Training.pdf)
487 [Notification-Training.pdf](https://nastad.org/sites/default/files/2021-12/PDF-Assisted-Partner-Notification-Training.pdf)
- 488 29. Ghanem KG, Ram S, Rice PA. The Modern Epidemic of Syphilis. *N Engl J Med*.
489 2020; 382(9):845–54. <https://doi.org/10.1056/NEJMra1901593>
- 490

491
492
493

Table 1. Demographic characteristics of PrEP¹ users for HIV in Brazil (2018-2020).

Variables (n)	n (%)
Sex at birth(34,000)	
Male	30,208 (89.0)
Female	3,771 (11.0)
Hermaphrodite	21 (<0.1)
Self-reported ethnicity/skin color (33,990)	
White	18,252 (53.7)
Pardo (Brown, i.e., mixed race)	10,945 (32.2)
Black	4,290 (12.6)
Yellow (i.e., Asian Brazilian)	359 (1.0)
Indigenous	144 (0.4)
Gender identity (34,000)	
Man	28,956 (85.2)
Transgender man	103 (0.3)
Woman	3,970 (12)
Transgender woman	790 (2.3)
Transvestite	181 (0.5)
Sexual Orientation (34,000)	
Bisexual	3,351 (9.9)
Heterosexual	6,092 (17.9)
Homosexual, gay, or lesbian	24,557 (72.2)
Schooling level² (33,991)	
1-3 years	193 (0.6)
4-7 years	1,616 (4.8)
8-11 years	9,071 (26.7)
12 years and over	23,040 (67.8)
None, no formal education	71 (0.2)

494 ¹ PrEP = Pre Exposure Prophylaxis; ² Schooling level: school complete years

495
496
497

498

499 **Table 2. Characterization of acquired syphilis before and during follow-**
 500 **up in HIV PrEP users, Brazil, 2018-2020.**

Variables	n (%)
Syphilis within 6 months before the initial PrEP appointment ¹(34,000*)	2,806 (8.3)
Active syphilis on return 30 days after initial appointment (19,440**)	
Yes	775 (4.0)
No	12,174 (62.6)
Not performed/unavailable	6,491 (33.4)
Active syphilis during HIV PrEP (19,820**)	
Yes	1,962 (9.8)
No	17,858 (90.1)
Active syphilis per follow-up appointment (79,753***)	
Yes	2,525 (3.2)
No	46,222 (58.0)
Not performed/unavailable	30,949 (38.8)
Number of active syphilis episodes per user (19,820**)	
0	17,858 (90.1)
1	1,590 (8)
2	290 (1.5)
3	65 (0.3)
4	15 (<0.1)
5	2 (<0.1)

501 * Study base population; ** Cohort population; *** Total follow-up appointments
 502 made.¹ PrEP = Pre Exposure Prophylaxis.

503

504

505

506

507

508

509

510 **Table 3. Characteristics of PrEP users and factors associated with syphilis during follow-up, Brazil, 2018-2020.**

Variable (n)	Syphilis episode during PrEP		RR*	95% CI	p-value ***	aOR#	95%CI##	p-value ***
	Yes n (%) (n=1,962)	No n (%) (n=17,858)						
Age (19,811)	32 ± 8 (31)**	33 ± 9 (31)**			0.366			<0.001
Sex at birth (19,810)								
Man	1,934 (98.6)	16,113(90.3)	1			1		
Woman	27 (1.4)	1,736 (9.7)	0.15	0.1-0.2	<0.001	0.3	0.2-0.5	<0.001
Sexual orientation (19,820)								
Heterosexual	76 (3.9)	2,813 (15.7)	1			1		
Homosexual/Gay/Lesbian	1,722 (87.8)	13,373(74.9)	4.3	3.4-5.4	<0.001	2.7	2.0-3.7	<0.001
Bisexual	164 (8.3)	1,672 (9.4)	3.4	2.6-4.4	<0.001	1.9	1.4-2.7	<0.001
Gender identity (19,820)								
Cisgender	1,889 (96.3)	17,423(97.6)	1					
Transgender	60 (3.0)	355 (2.0)	1.5	1.2-1.8	<0.001			
Travestis	13 (0.7)	80 (0.4)	1.4	0.9-2.4	0.174			
Ethnicity/skin color (19,816)								
Pardo (Brown, i.e., mixed race)	650 (33.1)	5,436 (30.4)	1			1		

White	1,043 (53.2)	9,964 (55.8)	0.9	0.8-0.98	0.02	0.8	0.7-0.9	<0.001
Black	234 (11.9)	2,192 (12.3)	0.9	0.8-1.1	0.18	0.8	0.7-0.99	0.04
Yellow (i.e., Asian Brazilian)	25 (1.3)	199 (1.1)	1.04	0.8-1.5	0.83	1.0	0.6-1.5	0.97
Indigenous	9 (0.4)	64 (0.3)	1.15	0.5-2.1	0.67	1.2	0.6-2.4	0.56
Schooling level (19,817)								
8-11 years	419 (21.0)	4,171 (23.4)	1			1		
None/No formal education	1 (<0.1)	24 (0.1)	0.4	0.1-3.0	0.374			
1-3 years	6 (0.3)	77 (0.2)	0.8	0.4-1.7	0.550			
4-7 years	46 (2.3)	669 (3.7)	0.7	0.5-0.9	0.017			
12 years and over	1,490 (76.0)	12,914(72.3)	1.1	1.0-1.6	0.017			
Accepted something in exchange for sex in the last 6 months (19,819)								
Yes	252 (13.0)	1,484 (8.3)	1.5	1.3-1.7	<0.001	1.6	1.3-1.9	<0.001
No	1,710 (87.0)	16,373(91.7)	1			1		
History of syphilis in the 6 months before PrEP (19,820)								
Yes	318 (16.2)	1,275 (7.1)	2.2	2.0-2.5	<0.001	2.2	1.9-2.5	<0.001
No/Unknown	1,644 (83.8)	16,583(92.9)	1		1			
Condom use in the last 3 months [‡](18,824)								

Never	408 (21.5)	4,240 (25.0)	1.3	1.1-1.5	<0.001	1.2	1.1-1.5	0.01
Less than half of the time	397 (20.9)	2,453 (14.5)	2.1	1.8-2.4	<0.001	1.7	1.5-2.0	<0.001
Half of the time	281 (14.8)	1,830 (10.8)	2.0	1.7-2.3	<0.001	1.7	1.5-2.1	<0.001
More than half of the time	489 (25.7)	3,895 (23.0)	1.7	1.4-1.9	<0.001	1.4	1.2-1.6	<0.001
Always	324 (17.0)	4,507 (26.7)	1			1		
Sexual partners in the last 3 months[‡]								
Men	18 ± 230 (4)	8 ± 36 (2)			<0.001			<0.001
Women	0.11±1.36(0)	0.20 ± 2.45(0)			<0.001			0.29
Trans women	0±0.05(0)	0.01±0.25 (0)			0.058			0.19
Trans men	0.01±0.13(0)	0.01±0.43(0)			0.006			
Travestis	0.01±0.35(0)	0.01± 0.54(0)			0.944			
Alcohol use^{‡§}(18,979)								
Yes	912 (47.0)	7,367 (43.0)	6.7	6.3-7.0	<0.001			
No	1,009 (53.0)	9,691 (57.0)	1					
Use of injectable drugs[‡](18,954)								
Yes	11 (0.6)	72 (0.4)	1.3	0.7-2.3	0.348			
No	1,913 (99.4)	16,958 (99.6)	1					
Use of other psychoactive drugs								
Poppers	120 (6.1)	425 (2.4)	2.5	2.1-2.9	<0.001	1.5	1.2-1.9	<0.001

Cocaine	210 (11.0)	905 (5.1)	2.1	1.8-2.4	<0.001	1.5	1.2-1.7	<0.001
Crack	1 (<0.1)	26 (0.1)	0.4	0.1-2.8	0.597			
Marijuana	425 (22.0)	2,716 (15.0)	1.5	1.4-1.7	<0.001	1.2	1.01-1.3	0.03
Club drugs (MDMA, GHB, ketamine, roofies, methamphetamine, and LSD)	216 (11.0)	1,237 (6.9)	1.7	1.5-1.9	<0.001			
Erection stimulants	220 (11.0)	1,126 (6.3)	1.8	1.6-2.1	<0.001	1.1	0.96-1.3	0.14
Solvents	22 (1.1)	101 (0.6)	2.0	1.4-3.0	<0.001			

511 * RR: Relative Risk ** Mean ± Standard Deviation (Median); *** Chi-square test;

512 ‡ Data from the last follow-up appointment § 5 doses or more in two hours; % Fischer exact test .# aOR: Adjusted Odds Ratio ## 95%CI: 95% Confidence Interval.

513 Akaike Information Criterion (AIC) = 11.367; pseudoR² = 0.157.